학술논문
Outcomes of keratolimbal allograft from ABO compatible donors for severe bilateral limbal stem cell deficiency
Document Type
Article
Author
Source
The Ocular Surface; January 2023, Vol. 27 Issue: 1 p48-53, 6p
Subject
Language
ISSN
15420124
Abstract
To report outcomes of keratolimbal allograft (KLAL) compatible for both human leukocyte (HLA) and/or blood type using oral prednisone, mycophenolate, and tacrolimus, with basiliximab if panel reactive antibodies (PRA) are present. Intravenous immunoglobulin (IVIG) was used post-operatively if donor-specific anti-HLA antibodies (DSA) were present.